TIAA Trust National Association Has $12.25 Million Stock Holdings in Boston Scientific Corporation $BSX

TIAA Trust National Association lessened its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 35.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 128,434 shares of the medical equipment provider’s stock after selling 69,056 shares during the quarter. TIAA Trust National Association’s holdings in Boston Scientific were worth $12,246,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Claret Asset Management Corp grew its holdings in shares of Boston Scientific by 4.4% in the 3rd quarter. Claret Asset Management Corp now owns 2,400 shares of the medical equipment provider’s stock valued at $234,000 after buying an additional 102 shares during the period. Cary Street Partners Investment Advisory LLC grew its holdings in shares of Boston Scientific by 5.1% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock valued at $206,000 after buying an additional 103 shares during the period. Outfitters Financial LLC grew its holdings in shares of Boston Scientific by 0.5% in the 4th quarter. Outfitters Financial LLC now owns 24,027 shares of the medical equipment provider’s stock valued at $2,291,000 after buying an additional 110 shares during the period. Fayez Sarofim & Co grew its holdings in shares of Boston Scientific by 2.1% in the 3rd quarter. Fayez Sarofim & Co now owns 5,327 shares of the medical equipment provider’s stock valued at $520,000 after buying an additional 111 shares during the period. Finally, Natural Investments LLC grew its holdings in shares of Boston Scientific by 2.9% in the 4th quarter. Natural Investments LLC now owns 4,036 shares of the medical equipment provider’s stock valued at $384,000 after buying an additional 112 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling

In related news, Director Edward J. Ludwig bought 3,580 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $56.68 per share, with a total value of $202,914.40. Following the purchase, the director owned 25,359 shares in the company, valued at approximately $1,437,348.12. This trade represents a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director David C. Habiger acquired 2,250 shares of Boston Scientific stock in a transaction dated Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, with a total value of $125,820.00. Following the completion of the purchase, the director owned 13,878 shares in the company, valued at approximately $776,057.76. The trade was a 19.35% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders purchased 9,800 shares of company stock valued at $554,012. Company insiders own 0.34% of the company’s stock.

Boston Scientific Price Performance

Shares of NYSE BSX opened at $48.92 on Wednesday. The firm has a market cap of $72.71 billion, a PE ratio of 20.47, a PEG ratio of 0.91 and a beta of 0.56. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 1-year low of $47.17 and a 1-year high of $109.50. The company has a fifty day moving average price of $57.28 and a 200 day moving average price of $75.83.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to analyst estimates of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same period in the prior year, the business earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Research analysts predict that Boston Scientific Corporation will post 3.36 earnings per share for the current fiscal year.

Boston Scientific declared that its board has approved a share buyback program on Monday, May 18th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical equipment provider to repurchase up to 6.4% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

BSX has been the subject of several research analyst reports. Zacks Research lowered shares of Boston Scientific from a “hold” rating to a “strong sell” rating in a report on Friday, June 5th. Barclays decreased their price target on shares of Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. Argus raised shares of Boston Scientific to a “strong-buy” rating in a report on Thursday, February 26th. Mizuho decreased their price target on shares of Boston Scientific from $115.00 to $90.00 and set an “outperform” rating for the company in a report on Monday, April 13th. Finally, UBS Group decreased their price target on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a report on Tuesday, March 17th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Boston Scientific currently has an average rating of “Moderate Buy” and a consensus target price of $85.92.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.